A Phase 3 interventional study of Amlodipine in Hypertension, sponsored by Pfizer. Completed at 9 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2009-10-28.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 110th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 40th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
16 studies in Hypertension by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 16 studies in Hypertension by Pfizer, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2007, is one of 3 in phase 3, and was the 8th registered.
Pfizer’s Hypertension studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Pfizer’s 16 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the safety and efficacy of the long-term use of amlodipine 10 mg in subjects who will be able to enter a long-term study after completing the parent study "A double-blind comparative study between amlodipine 5 mg and 10 mg in patients with essential hypertension for whom amlodipine 5 mg is insufficiently effective" (Protocol No.: A0531085).
NCT00415623 (protocol A0531085)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Amlodipine
Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
Change in Systolic Blood Pressure From Baseline of the Preceding Study
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Systolic Blood Pressure From Baseline of This Long-term Study
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Diastolic Blood Pressure From Baseline of the Preceding Study
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Diastolic Blood Pressure From Baseline of This Long-term Study
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Systolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Systolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Diastolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Change in Diastolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value in Treatment Groups With or Without Concomitant Antihypertensive Agent
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
| Milestone | Amlodipine |
|---|---|
| Started | 134 |
| Completed | 116 |
| Not completed | 18 |
| Withdrew: Adverse event | 16 |
| Withdrew: Move | 1 |
| Withdrew: Withdrawal by subject | 1 |
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
| mmHg | Amlodipine | The Preceding Study 5 mg Sub-set of This Long-term Study | The Preceding Study 10 mg Sub-set of This Long-term Study |
|---|---|---|---|
| Week 0: Baseline (Actual Value) | 148.8 ± 8.3 | 148.8 ± 8.0 | 148.8 ± 8.7 |
| Week 8 | -8.7 ± 12.0 | -5.6 ± 12.9 | -12.0 ± 10.1 |
| Week 10 | -14.8 ± 11.5 | -14.5 ± 11.3 | -15.0 ± 11.8 |
| Week 12 | -15.6 ± 10.0 | -15.6 ± 9.7 | -15.7 ± 10.4 |
| Week 16 | -16.7 ± 10.7 | -16.9 ± 10.5 | -16.4 ± 10.9 |
| Week 20 | -15.8 ± 10.4 | -17.4 ± 11.1 | -14.1 ± 9.4 |
| Week 24 | -15.4 ± 11.2 | -16.1 ± 10.5 | -14.6 ± 11.9 |
| Week 28 | -14.7 ± 11.3 | -15.7 ± 11.7 | -13.6 ± 11.0 |
| Week 32 | -13.8 ± 12.7 | -14.4 ± 12.4 | -13.2 ± 13.2 |
| Week 36 | -13.4 ± 12.3 | -14.6 ± 12.0 | -12.2 ± 12.6 |
| Week 40 | -13.9 ± 11.4 | -14.7 ± 11.6 | -13.0 ± 11.1 |
| Week 44 | -15.7 ± 12.1 | -15.6 ± 12.5 | -15.8 ± 11.8 |
| Week 48 | -15.3 ± 11.4 | -16.0 ± 11.6 | -14.5 ± 11.2 |
| Week 52 | -15.6 ± 11.5 | -15.0 ± 11.7 | -16.3 ± 11.3 |
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
| mmHg | Amlodipine | The Preceding Study 5 mg Sub-set of This Long-term Study | The Preceding Study 10 mg Sub-set of This Long-term Study |
|---|---|---|---|
| Week 8: Baseline (Actual Value) | 140.1 ± 14.2 | 143.2 ± 15.7 | 136.8 ± 11.6 |
| Week 10 | -6.0 ± 10.9 | -8.9 ± 11.2 | -3.0 ± 9.8 |
| Week 12 | -6.9 ± 11.9 | -10.0 ± 13.6 | -3.7 ± 8.8 |
| Week 16 | -8.0 ± 12.0 | -11.3 ± 13.3 | -4.4 ± 9.4 |
| Week 20 | -7.1 ± 12.0 | -11.8 ± 12.7 | -2.1 ± 9.0 |
| Week 24 | -6.7 ± 12.4 | -10.5 ± 12.7 | -2.6 ± 10.8 |
| Week 28 | -6.0 ± 13.0 | -10.1 ± 13.9 | -1.6 ± 10.3 |
| Week 32 | -5.1 ± 12.2 | -8.8 ± 13.0 | -1.2 ± 9.9 |
| Week 36 | -4.7 ± 12.6 | -9.0 ± 13.2 | -0.2 ± 10.4 |
| Week 40 | -5.2 ± 13.7 | -9.1 ± 14.9 | -1.0 ± 10.9 |
| Week 44 | -7.0 ± 12.6 | -10.0 ± 14.1 | -3.8 ± 10.0 |
| Week 48 | -6.6 ± 13.4 | -10.4 ± 14.4 | -2.5 ± 10.9 |
| Week 52 | -6.9 ± 13.0 | -9.4 ± 14.0 | -4.3 ± 11.4 |
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
| mmHg | Amlodipine | The Preceding Study 5 mg Sub-set of This Long-term Study | The Preceding Study 10 mg Sub-set of This Long-term Study |
|---|---|---|---|
| Week 0: Baseline (Actual Value) | 86.3 ± 10.2 | 87.6 ± 10.0 | 84.8 ± 10.2 |
| Week 8 | -3.1 ± 8.8 | -1.8 ± 9.4 | -4.5 ± 7.9 |
| Week 10 | -6.4 ± 7.9 | -6.6 ± 7.7 | -6.3 ± 8.1 |
| Week 12 | -6.9 ± 7.6 | -7.7 ± 7.9 | -6.0 ± 7.2 |
| Week 16 | -7.3 ± 8.0 | -8.4 ± 8.0 | -6.2 ± 7.9 |
| Week 20 | -7.2 ± 8.0 | -7.9 ± 8.0 | -6.4 ± 7.9 |
| Week 24 | -6.8 ± 8.1 | -7.1 ± 8.6 | -6.5 ± 7.6 |
| Week 28 | -6.8 ± 8.3 | -7.8 ± 8.9 | -5.7 ± 7.5 |
| Week 32 | -6.8 ± 8.6 | -7.1 ± 8.5 | -6.5 ± 8.8 |
| Week 36 | -6.5 ± 8.4 | -7.4 ± 7.9 | -5.5 ± 8.9 |
| Week 40 | -6.8 ± 8.7 | -7.2 ± 9.6 | -6.3 ± 7.8 |
| Week 44 | -7.3 ± 8.0 | -7.6 ± 8.2 | -6.9 ± 7.8 |
| Week 48 | -7.2 ± 8.8 | -7.3 ± 9.4 | -7.0 ± 8.2 |
| Week 52 | -7.9 ± 8.5 | -8.2 ± 7.9 | -7.7 ± 9.2 |
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
| mmHg | Amlodipine | The Preceding Study 5 mg Sub-set of This Long-term Study | The Preceding Study 10 mg Sub-set of This Long-term Study |
|---|---|---|---|
| Week 8: Baseline (Actual Value) | 83.1 ± 11.5 | 85.8 ± 11.8 | 80.3 ± 10.5 |
| Week 10 | -3.3 ± 7.2 | -4.8 ± 7.5 | -1.7 ± 6.6 |
| Week 12 | -3.7 ± 7.3 | -5.8 ± 8.1 | -1.5 ± 5.6 |
| Week 16 | -4.2 ± 7.9 | -6.5 ± 8.3 | -1.7 ± 6.6 |
| Week 20 | -4.1 ± 7.5 | -6.1 ± 8.3 | -1.9 ± 5.8 |
| Week 24 | -3.7 ± 8.4 | -5.3 ± 8.4 | -2.0 ± 8.2 |
| Week 28 | -3.7 ± 8.3 | -6.0 ± 8.8 | -1.2 ± 6.9 |
| Week 32 | -3.6 ± 8.4 | -5.2 ± 8.3 | -1.9 ± 8.3 |
| Week 36 | -3.3 ± 9.2 | -5.6 ± 9.1 | -0.9 ± 8.7 |
| Week 40 | -3.6 ± 9.1 | -5.4 ± 9.8 | -1.7 ± 8.0 |
| Week 44 | -4.1 ± 8.3 | -5.8 ± 8.7 | -2.3 ± 7.4 |
| Week 48 | -4.1 ± 8.7 | -5.5 ± 9.5 | -2.5 ± 7.6 |
| Week 52 | -4.8 ± 9.6 | -6.3 ± 9.5 | -3.2 ± 9.5 |
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
| mmHg | Subjects With Concomitant Antihypertensive Agent | Subjects Without Concomitant Antihypertensive Agent |
|---|---|---|
| Week 0: Baseline (Actual Value) | 153.9 ± 10.8 | 148.3 ± 7.9 |
| Week 8 (n=13, 121) | -4.8 ± 8.1 | -9.1 ± 12.3 |
| Week 10 (n=13, 118) | -13.8 ± 8.7 | -14.8 ± 11.8 |
| Week 12 (n=12, 119) | -13.5 ± 8.0 | -15.8 ± 9.9 |
| Week 16 (n=12, 117) | -17.2 ± 8.9 | -16.4 ± 10.5 |
| Week 20 (n=12, 116) | -10.8 ± 6.0 | -16.1 ± 10.3 |
| Week 24 (n=11, 113) | -13.8 ± 14.0 | -14.8 ± 10.2 |
| Week 28 (n=12, 111) | -15.1 ± 10.9 | -13.6 ± 10.4 |
| Week 32 (n=12, 111) | -4.8 ± 13.9 | -14.0 ± 11.7 |
| Week 36 (n=11, 108) | -4.8 ± 13.2 | -13.1 ± 11.5 |
| Week 40 (n=12, 108) | -9.6 ± 8.3 | -13.6 ± 10.9 |
| Week 44 (n=11, 108) | -13.7 ± 8.3 | -15.4 ± 12.0 |
| Week 48 (n=9, 107) | -11.1 ± 12.5 | -15.3 ± 10.6 |
| Week 52 (n=9, 106) | -10.8 ± 8.5 | -15.9 ± 11.0 |
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
| mmHg | Subjects With Concomitant Antihypertensive Agent | Subjects Without Concomitant Antihypertensive Agent |
|---|---|---|
| Week 8: Baseline (Actual Value) | 149.1 ± 15.1 | 139.2 ± 13.8 |
| Week 10 (n=13, 118) | -9.0 ± 9.0 | -5.9 ± 11.2 |
| Week 12 (n=12, 119) | -8.4 ± 9.2 | -6.9 ± 12.2 |
| Week 16 (n=12, 117) | -12.0 ± 9.8 | -7.6 ± 12.3 |
| Week 20 (n=12, 116) | -5.6 ± 8.6 | -7.3 ± 12.3 |
| Week 24 (n=11, 113) | -9.2 ± 15.4 | -6.2 ± 12.1 |
| Week 28 (n=12, 111) | -9.9 ± 13.1 | -5.0 ± 12.7 |
| Week 32 (n=12, 111) | 0.4 ± 17.5 | -5.3 ± 11.5 |
| Week 36 (n=11, 108) | 0.2 ± 18.7 | -4.5 ± 12.0 |
| Week 40 (n=12, 108) | -4.5 ± 11.2 | -5.2 ± 14.1 |
| Week 44 (n=11, 108) | -9.1 ± 13.2 | -7.1 ± 12.6 |
| Week 48 (n=9, 107) | -7.3 ± 17.4 | -7.0 ± 13.2 |
| Week 52 (n=9, 106) | -7.1 ± 13.9 | -7.5 ± 13.1 |
Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)
| mmHg | Subjects With Concomitant Antihypertensive Agent | Subjects Without Concomitant Antihypertensive Agent |
|---|---|---|
| Week 0: Baseline (Actual Value) | 85.9 ± 12.4 | 86.3 ± 10.0 |
| Week 8 (n=13, 121) | 0.3 ± 9.9 | -3.5 ± 8.6 |
| Week 10 (n=13, 118) | -3.6 ± 9.1 | -6.6 ± 7.7 |
| Week 12 (n=12, 119) | -4.8 ± 9.7 | -7.0 ± 7.4 |
| Week 16 (n=12, 117) | -4.9 ± 9.2 | -7.6 ± 8.0 |
| Week 20 (n=12, 116) | -2.5 ± 9.3 | -7.7 ± 7.9 |
| Week 24 (n=11, 113) | -2.9 ± 10.3 | -6.9 ± 8.1 |
| Week 28 (n=12, 111) | -3.2 ± 7.5 | -6.9 ± 8.6 |
| Week 32 (n=12, 111) | 1.7 ± 7.6 | -7.4 ± 8.6 |
| Week 36 (n=11, 108) | 2.1 ± 8.6 | -7.0 ± 8.2 |
| Week 40 (n=12, 108) | 0.8 ± 6.8 | -7.3 ± 8.8 |
| Week 44 (n=11, 108) | -2.4 ± 7.0 | -7.5 ± 8.2 |
| Week 48 (n=9, 107) | -0.8 ± 9.4 | -7.5 ± 9.0 |
| Week 52 (n=9, 106) | -2.7 ± 7.3 | -8.4 ± 8.9 |
Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)
| mmHg | Subjects With Concomitant Antihypertensive Agent | Subjects Without Concomitant Antihypertensive Agent |
|---|---|---|
| Week 8: Baseline (Actual Value) | 86.2 ± 11.8 | 82.8 ± 11.4 |
| Week 10 (n=13, 118) | -3.9 ± 5.4 | -3.3 ± 7.5 |
| Week 12 (n=12, 119) | -5.0 ± 4.9 | -3.7 ± 7.6 |
| Week 16 (n=12, 117) | -5.1 ± 5.0 | -4.2 ± 8.2 |
| Week 20 (n=12, 116) | -2.8 ± 6.4 | -4.4 ± 7.7 |
| Week 24 (n=11, 113) | -4.0 ± 8.4 | -3.6 ± 8.7 |
| Week 28 (n=12, 111) | -3.5 ± 8.6 | -3.6 ± 8.4 |
| Week 32 (n=12, 111) | 1.5 ± 9.8 | -4.2 ± 8.4 |
| Week 36 (n=11, 108) | 2.3 ± 11.8 | -3.8 ± 9.2 |
| Week 40 (n=12, 108) | 0.6 ± 6.6 | -4.1 ± 9.6 |
| Week 44 (n=11, 108) | -3.4 ± 9.2 | -4.4 ± 8.5 |
| Week 48 (n=9, 107) | -1.9 ± 11.0 | -4.6 ± 8.9 |
| Week 52 (n=9, 106) | -3.8 ± 10.2 | -5.4 ± 10.1 |
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
| participants | Amlodipine | The Preceding Study 5 mg Sub-set of This Long-term Study | The Preceding Study 10 mg Sub-set of This Long-term Study |
|---|---|---|---|
| Week 8 | 41 | 15 | 26 |
| Week 10 | 59 | 27 | 32 |
| Week 12 | 64 | 30 | 34 |
| Week 16 | 62 | 29 | 33 |
| Week 20 | 65 | 35 | 30 |
| Week 24 | 64 | 32 | 32 |
| Week 28 | 54 | 30 | 24 |
| Week 32 | 53 | 23 | 30 |
| Week 36 | 56 | 32 | 24 |
| Week 40 | 56 | 29 | 27 |
| Week 44 | 58 | 26 | 32 |
| Week 48 | 58 | 31 | 27 |
| Week 52 | 63 | 29 | 34 |
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
| participants | Amlodipine | The Preceding Study 5 mg Sub-set of This Long-term Study | The Preceding Study 10 mg Sub-set of This Long-term Study |
|---|---|---|---|
| Week 8 | 36 | 13 | 23 |
| Week 10 | 55 | 25 | 30 |
| Week 12 | 60 | 29 | 31 |
| Week 16 | 59 | 28 | 31 |
| Week 20 | 62 | 35 | 27 |
| Week 24 | 60 | 30 | 30 |
| Week 28 | 54 | 30 | 24 |
| Week 32 | 50 | 22 | 28 |
| Week 36 | 54 | 32 | 22 |
| Week 40 | 52 | 27 | 25 |
| Week 44 | 57 | 25 | 32 |
| Week 48 | 56 | 30 | 26 |
| Week 52 | 60 | 28 | 32 |
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
| participants | Subjects With Concomitant Antihypertensive Agent | Subjects Without Concomitant Antihypertensive Agent |
|---|---|---|
| Week 8 (n=13, 121) | 2 | 39 |
| Week 10 (n=13, 118) | 3 | 54 |
| Week 12 (n=12, 119) | 4 | 59 |
| Week 16 (n=12, 117) | 4 | 56 |
| Week 20 (n=12, 116) | 3 | 59 |
| Week 24 (n=11, 113) | 2 | 57 |
| Week 28 (n=12, 111) | 2 | 46 |
| Week 32 (n=12, 111) | 2 | 46 |
| Week 36 (n=11, 108) | 2 | 45 |
| Week 40 (n=12, 108) | 1 | 48 |
| Week 44 (n=11, 108) | 1 | 49 |
| Week 48 (n=9, 107) | 1 | 49 |
| Week 52 (n=9, 106) | 1 | 54 |
Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg
| participants | Subjects With Concomitant Antihypertensive Agent | Subjects Without Concomitant Antihypertensive Agent |
|---|---|---|
| Week 8 (n=13, 121) | 1 | 35 |
| Week 10 (n=13, 118) | 3 | 50 |
| Week 12 (n=12, 119) | 4 | 55 |
| Week 16 (n=12, 117) | 4 | 53 |
| Week 20 (n=12, 116) | 3 | 56 |
| Week 24 (n=11, 113) | 2 | 53 |
| Week 28 (n=12, 111) | 2 | 46 |
| Week 32 (n=12, 111) | 2 | 43 |
| Week 36 (n=11, 108) | 2 | 43 |
| Week 40 (n=12, 108) | 1 | 44 |
| Week 44 (n=11, 108) | 1 | 48 |
| Week 48 (n=9, 107) | 1 | 47 |
| Week 52 (n=9, 106) | 1 | 51 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine | — | 8/134 (6%) | 50/134 (37.3%) |
| Event | Amlodipine |
|---|---|
| FallInjury, poisoning and procedural complications | 2/134 |
| Loss of consciousnessNervous system disorders | 2/134 |
| Angina unstableCardiac disorders | 1/134 |
| Atrioventricular blockCardiac disorders | 1/134 |
| Sick sinus syndromeCardiac disorders | 1/134 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/134 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/134 |
| Gum neoplasm malignant stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/134 |
| Malignant ascitesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/134 |
| Cerebral infarctionNervous system disorders | 1/134 |
| Event | Amlodipine |
|---|---|
| NasopharyngitisInfections and infestations | 33/134 |
| Oedema peripheralGeneral disorders | 15/134 |
| Back painMusculoskeletal and connective tissue disorders | 9/134 |
| Age, Customized(participants) | Amlodipine |
|---|---|
| 20 to 44 years | 13 |
| 45 to 64 years | 65 |
| >=65 years | 56 |
| Sex: Female, Male(Participants) | Amlodipine |
|---|---|
| Female | 61 |
| Male | 73 |
The record gives a start of May 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine